The Effect Of Saxagliptin Monotheragy On Treating New Type2Diabetes

Objective To evaluate the efficacy and safety of saxagliptin monotherapy on those Type2Diabetic Patients who newly diagnosed or never use oral medicines or Insulin for therapy before.Methods We chose21T2DM patients, and divided them into experimental group and control group randomly. The experimental group were given saxagliptin5mg once daily, and the control group were given the same quantity of placebo. Fasting plasma glucose(FPG), postprandial2hours plasma glucose(2hPG), glycosylated haemoglobin(HbAlc) and body mass index (BMI) were measured and compared after the treatment.Results After the treatment, the HbAlc of the experimental group declined by14.93±8.66%, and had statistically difference with the control group6.70±6.75%(P＜0.05). For the experimental group, fasting plasma glucose9.46±1.90mmol/L, postprandial2hours plasma glucose11.88±3.13mmol/L, after the treatment, fasting plasma glucose6.99±0.65mmol/L, postprandial2hours plasma glucose8.41±1.42mmol/L both decreased significantly(P＜0.05). But for the control group, they had no statistical difference (P＞0.05). Fasting blood sugar declined by24.18±13.09%after experimental treatment, and postprandial2hours plasma glucose fell by27.23±10.02%, had statistically difference from the control group (P<0.05). Compared with pretreatment, BMI of the experimental group dropped from25.90±4.24kg/m2to24.88±3.95kg/m2(P＜0.05). BMI of the control grope had no statistical difference (P＞0.05). Conclusion Saxagliptin is effective for new type2diabetes. But its long-term efficacy and safety still need to be confirmed by more RCTs.